Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Mar 6;14(3):310.
doi: 10.3390/biom14030310.

Post-Translational Modifications and Diabetes

Chiranjeev Sharma  1 , Abu Hamza  1 , Emily Boyle  1 , Dickson Donu  1 , Yana Cen  1   2
Affiliations
Review

Post-Translational Modifications and Diabetes

Chiranjeev Sharma et al. Biomolecules. .

Abstract

Diabetes and its associated complications have increasingly become major challenges for global healthcare. The current therapeutic strategies involve insulin replacement therapy for type 1 diabetes (T1D) and small-molecule drugs for type 2 diabetes (T2D). Despite these advances, the complex nature of diabetes necessitates innovative clinical interventions for effective treatment and complication prevention. Accumulative evidence suggests that protein post-translational modifications (PTMs), including glycosylation, phosphorylation, acetylation, and SUMOylation, play important roles in diabetes and its pathological consequences. Therefore, the investigation of these PTMs not only sheds important light on the mechanistic regulation of diabetes but also opens new avenues for targeted therapies. Here, we offer a comprehensive overview of the role of several PTMs in diabetes, focusing on the most recent advances in understanding their functions and regulatory mechanisms. Additionally, we summarize the pharmacological interventions targeting PTMs that have advanced into clinical trials for the treatment of diabetes. Current challenges and future perspectives are also provided.

Keywords: T1D; T2D; clinical trials; diabetes; post-translational modifications.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PTMs in diabetes. The figure was created with BioRender.com.
See this image and copyright information in PMC

References

    1. Sun H., Saeedi P., Karuranga S., Pinkepank M., Ogurtsova K., Duncan B.B., Stein C., Basit A., Chan J.C.N., Mbanya J.C., et al. IDF Diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045. Diabetes Res. Clin. Pract. 2022;183:109119. doi: 10.1016/j.diabres.2021.109119. - DOI - PMC - PubMed
    1. Tremblay J., Hamet P. Environmental and genetic contributions to diabetes. Metabolism. 2019;100:153952. doi: 10.1016/j.metabol.2019.153952. - DOI - PubMed
    1. Chakkalakal R.J., Galaviz K.I., Sathish T., Shah M.K., Narayan K.M.V. Test and Treat for Prediabetes: A Review of the Health Effects of Prediabetes and the Role of Screening and Prevention. Annu. Rev. Public Health. 2023. online ahead of print . - DOI - PubMed
    1. Diaz-Santana M.V., O’Brien K.M., Park Y.M., Sandler D.P., Weinberg C.R. Persistence of Risk for Type 2 Diabetes after Gestational Diabetes Mellitus. Diabetes Care. 2022;45:864–870. doi: 10.2337/dc21-1430. - DOI - PMC - PubMed
    1. Ley S.H., Hamdy O., Mohan V., Hu F.B. Prevention and management of type 2 diabetes: Dietary components and nutritional strategies. Lancet. 2014;383:1999–2007. doi: 10.1016/S0140-6736(14)60613-9. - DOI - PMC - PubMed